Claude Sardet

Dr. Claude Sardet


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EOEsin Orhan
Esin Orhan
CVCarolina Velazquez
Carolina Velazquez
ITImene Tabet
Imene Tabet
CSClaude Sardet
Claude Sardet
Charles TheilletCharles Theillet
Charles Theillet
The RAD51 recombinase is a critical effector of Homologous Recombination (HR), which is an essential DNA repair mechanism for double-strand breaks. The RAD51 protein is recruited onto the DNA break by BRCA2 and forms homopolymeric filaments that invade the homologous chromatid and use it as a template for repair. RAD51 filaments are detectable by immunofluorescence as distinct foci in the cell nucleus, and their presence is a read out of HR proficiency. RAD51 is an essential gene, protecting cells from genetic instability. Its expression is low and tightly regulated in normal cells and, contrastingly, elevated in a large fraction of cancers, where its level of expression and activity have been linked with sensitivity to genotoxic treatment. In particular, BRCA-deficient tumors show reduced or obliterated RAD51 foci formation and increased sensitivity to platinum salt or PARP inhibitors. However, resistance to treatment sets in rapidly and is frequently based on a complete or partial restoration of RAD51 foci formation. Consequently, RAD51 could be a highly valuable therapeutic target. Here, we review the multiple levels of regulation that impact the transcription of the RAD51 gene, as well as the post-translational modifications that determine its expression level, recruitment on DNA damage sites and the efficient formation of homofilaments. Some of these regulation levels may be targeted and their impact on cancer cell survival discussed.

1 April 2015 in Cell Reports
Verified
Journal Article
Open access
GRGenevieve Rodier
Genevieve Rodier
OKOlivier Kirsh
Olivier Kirsh
MBMartín Baraibar
Martín Baraibar
THThibault Houlès
Thibault Houlès
MLMatthieu Lacroix
Matthieu Lacroix
CSClaude Sardet
Claude Sardet
Recent data support the notion that a group of key transcriptional regulators involved in tumorigenesis, including MYC, p53, E2F1, and BMI1, share an intriguing capacity to simultaneously regulate metabolism and cell cycle. Here, we show that another factor, the multifunctional protein E4F1, directly controls genes involved in mitochondria functions and cell-cycle checkpoints, including Chek1, a major component of the DNA damage response. Coordination of these cellular functions by E4F1 appears essential for the survival of p53-deficient transformed cells. Acute inactivation of E4F1 in these cells results in CHK1-dependent checkpoint deficiency and multiple mitochondrial dysfunctions that lead to increased ROS production, energy stress, and inhibition of de novo pyrimidine synthesis. This deadly cocktail leads to the accumulation of uncompensated oxidative damage to proteins and extensive DNA damage, ending in cell death. This supports the rationale of therapeutic strategies simultaneously targeting mitochondria and CHK1 for selective killing of p53-deficient cancer cells.

12 September 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MLMatthieu Lacroix
Matthieu Lacroix
GRGeneviève Rodier
Geneviève Rodier
OKOlivier Kirsh
Olivier Kirsh
THThibault Houles
Thibault Houles
HDHélène Delpech
Hélène Delpech
CSClaude Sardet
Claude Sardet
Significance: Pyruvate dehydrogenase (PDH) deficiency is the cause of several human metabolic diseases. In mammals, the transcriptional control of PDH complex components and its impact on pathophysiology remain poorly understood. We show that E4 transcription factor 1 (E4F1) controls a transcriptional program essential for PDH activity that involves genes linked to human metabolic syndromes. Genetic inactivation of murine E4f1 results in a strong decrease of PDH activity and severe perturbations of pyruvate metabolism. In concordance with the work of Legati et al., we show that striated muscle-specific E4f1 KO animals display phenotypes that recapitulate these clinical symptoms, providing an exciting clinical perspective to the present work.

12 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SAStéphanie Arnould
Stéphanie Arnould
GRGeneviève Rodier
Geneviève Rodier
GMGisèle Matar
Gisèle Matar
CVCharles Vincent
Charles Vincent
NPNelly Pirot
Nelly Pirot
CSClaude Sardet
Claude Sardet
Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition

Verified
Journal Article
Open access
PDF file
KBKalil Batnini
Kalil Batnini
THThibault Houles
Thibault Houles
OKOlivier Kirsh
Olivier Kirsh
SMStanislas Du Manoir
Stanislas Du Manoir
MZMehdi Zaroual
Mehdi Zaroual
GRGenevieve Rodier
Genevieve Rodier
E4F1 is essential for early embryonic mouse development and for controlling the balance between proliferation and survival of actively dividing cells. We previously reported that E4F1 is essential for the survival of murine p53-deficient cancer cells by controlling the expression of genes involved in mitochondria functions and metabolism, and in cell-cycle checkpoints, including CHEK1, a major component of the DNA damage and replication stress responses. Here, combining ChIP-Seq and RNA-Seq approaches, we identified the transcriptional program directly controlled by E4F1 in Human Triple-Negative Breast Cancer cells (TNBC). E4F1 binds and regulates a limited list of direct target genes (57 genes) in these cells, including the human CHEK1 gene and, surprisingly, also two other genes encoding post-transcriptional regulators of the ATM/ATR-CHK1 axis, namely, the TTT complex component TTI2 and the phosphatase PPP5C, that are essential for the folding and stability, and the signaling of ATM/ATR kinases, respectively. Importantly, E4F1 also binds the promoter of these genes in vivo in Primary Derived Xenograft (PDX) of human TNBC. Consequently, the protein levels and signaling of CHK1 but also of ATM/ATR kinases are strongly downregulated in E4F1-depleted TNBC cells resulting in a deficiency of the DNA damage and replicative stress response in these cells. The E4F1-depleted cells fail to arrest into S-phase upon treatment with the replication-stalling agent Gemcitabine, and are highly sensitized to this drug, as well as to other DNA-damaging agents, such as Cisplatin. Altogether, our data indicate that in breast cancer cells the ATM/ATR-CHK1 signaling pathway and DNA damage-stress response are tightly controlled at the transcriptional and post-transcriptional level by E4F1.

29 November 2018 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
CPConception Paul
Conception Paul
HDHélène Delpech
Hélène Delpech
DHDelphine Haouzi
Delphine Haouzi
SHSamir Hamamah
Samir Hamamah
CSClaude Sardet
Claude Sardet
EFeric fabbrizio
eric fabbrizio
Repression of retro‐transposons is essential for genome integrity during germ cell development and is tightly controlled through epigenetic mechanisms. In primordial germ cells, Prmt5 is involved in retro‐transposon repression by methylating Piwi proteins, which is part of the piRNA pathway. Here, we show that in mice, genetic inactivation of coprs (which is highly expressed in testis and encodes a histone‐binding protein required for the targeting of Prmt5 activity) affects the maturation of spermatogonia to spermatids. Mass spectrometry analysis revealed the presence of Miwi in testis protein lysates immunoprecipitated with an anti‐Coprs antibody. The observed deregulation of Miwi and pachytene pre‐piRNAs levels, and the de‐repression of LINE1 repetitive sequences observed in coprs ‐/‐ mice, suggest that Coprs is implicated in genome surveillance mechanisms.